These conditions include estrogen deficiency–related bone loss, inflammatory bone destruction and diabetes-associated skeletal fragility, etc. Evidence from both animal models and human studies has begun to clarify how GIP signaling behaves under these stress conditions. The gene discussed is GIP; the disease is diabetes mellitus.